DC
Decheng Capital Global Life Sciences Fund IV, L.P. cut its UPB stake below 5%
Decheng Capital Global Life Sciences Fund IV, L.P. reported owning 4.9% of Upstream Bio, Inc. (UPB) (2,724,868 shares) in a Schedule 13G filed Oct 29, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.